Explore /
Poster
/ Rates of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T).

Rates of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T).

Authors

Matthew J. Frigault

Massachusetts General Hospital, Boston, MA

Matthew J. Frigault , Theresa Amoloja , Lea Micaletti Burke , Rodica Morariu-Zamfir , Valkal Bhatt , Kristen Bibeau , Xiao Ying Tang , Amy Moskop , Richard T. Maziarz , John F. DiPersio

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Cell Therapy, Bispecific Antibodies, and Autologous Stem Cell Transplantation for NHL, HL, or CLL

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 7528)

DOI

10.1200/JCO.2023.41.16_suppl.7528

Abstract #

7528

Poster Bd #

Abstract Disclosures

Similar Posters

Poster

2021 ASCO Annual Meeting

IL-1 receptor antagonist for prevention of severe immune effector cell-associated neurotoxicity syndrome.

First Author: Caspian Oliai

Poster

2024 ASCO Annual Meeting

$Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy.$